AADI Earnings

AADI reported its FY2024Q2 earnings on 2024-08-07, showcasing a revenue of 6.18M against an estimate of 6.10M, resulting in a 1.3% surprise. The EPS was -0.54, surpassing the expected -0.71 by 23.94%. The stock experienced a -3.57% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following AADI's FY2024Q2 earnings announcement on 2024-08-07, the stock price moved by -3.57% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, AADI's stock price tends to shift by an average of 5.3% in the 10 days leading up to earnings and 8.26% in the 10 days following, providing insight into potential market.

For 2025/Q1, analysts estimate AADI's annual revenue to reach 6.72M, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between AADI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2024 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, AADI's stock price typically moves by 5.3% in the 10 days before its earnings and 8.26% in the 10 days after. For the upcoming 2025/Q1 earnings, analysts expect an EPS of undefined and revenue of 6.72M.

The earnings call presents a mixed picture: stable financial performance with a decrease in net loss and increased FYARRO sales, but ongoing financial challenges and risks from clinical trials. The Q&A section highlights management's uncertainty in key areas, like TSC1 and 2 expectations, and vague responses on sales potential, which may concern investors. Despite positive cash flow and a promising market opportunity, uncertainties in trial outcomes and market adoption, along with lack of guidance, suggest a neutral short-term stock price movement.